Overview
CAR T therapy has revolutionized treatment for relapsed or refractory large B-cell lymphoma (LBCL), yet its real-world adoption remains limited. This study, leveraging data from the Flatiron Health Research Database, assessed real-world treatment patterns and outcomes for LBCL patients eligible for second-line (2L) and third-line (3L) therapies. It compared the effectiveness of CAR T therapy to traditional treatments like R-ICE/DHAP across different time frames, as regulatory approval has evolved into earlier treatment settings. Findings showed that CAR T therapy significantly extended the time to next treatment and improved overall survival compared to non-CAR T therapies.
Why this matters
The research highlights CAR T therapy's potential to transform LBCL treatment by providing longer disease control and better survival outcomes than conventional therapies. By demonstrating CAR T's efficacy in both 2L and 3L settings, the study supports its expanded use earlier in the treatment process and a reevaluation of current treatment guidelines, ensuring more patients benefit from this innovative therapy.